• September 3 (THU)
  • September 4 (FRI)

Sep. 3 (Thu)

Scientific Symposium 1

Cutting edge of immuno-oncology
Date & Time Sep. 3 (Thu), 09:00-10:30 Venue Room A
Speaker
  1. 1.Neoadjuvant checkpoint blockade for cancer immunotherapy
  2. 2.Novel biomarkers for immuno-oncology
  3. 3.Cutting-edge preclinical models for cancer immunotherapy research

Scientific Symposium 2

Progress in precision medicine
Date & Time Sep. 3 (Thu), 09:00-10:30 Venue Room B
Speaker
  1. 1.New uses of existing targeted drugs: DRUP Trial by the Netherlands Cancer Institute
    Emile VOEST (Netherlands Cancer Institute, Netherlands)
  2. 2.MASTER KEY project: a biomarker-driven platform trial for rare cancers
    Yasuhiro Fujiwara (National Cancer Center Hospital, Japan)
  3. 3.Comprehensive Genomic Profiling in Translational Cancer Research
    Tae Min KIM (Seoul National University Hospital, Korea)
  4. 4.Incorporating imaging biomarkers in clinical trial design
    Kyung Won KIM (Asan Medical Center, Korea)

Scientific Symposium 3

Discovery of novel therapeutic targets
Date & Time Sep. 3 (Thu), 09:00-10:30 Venue Room C
Speaker
  1. 1.KRAS: An undruggable drug target that drives antitumor activity and anti-tutmor immunity
  2. 2.Axl: new target that reprograms the immunological microenvironment combined with radiotherapy
    Amato J. GIACCIA (Stanford University, USA)
  3. 3.YAP-TEAD binding: Therapeutic approach for targeting HIPPO signaling pathway
    Hwan Jung LIM (Korea Research Institute of Chemical Technology, Korea)

Plenary Lecture 1

Date & Time Sep. 3 (Thu), 10:50-11:30 Venue Room A
Speaker Implementing a comprehensive translational oncology platform in precision medicine: challenges, opportunities, and new directions
Gordon Mills (OHSU, USA)

Plenary Lecture 2

Date & Time Sep. 3 (Thu), 11:30-12:10 Venue Room A
Speaker TBD
Amato J. GIACCIA (Stanford University, USA)

Special Symposium 1

Regulatory science
Date & Time Sep. 3 (Thu), 13:20-14:20 Venue Room A
Speaker
  1. 1.The way to scientific regulation
  2. 2.How to prepare approval, Tips for drug developers & investigators
    Myung A Chung (National Institute of Food and Drug Safety Evaluation, Korea)

Scientific Symposium 4

CRC
Date & Time Sep. 3 (Thu), 13:20-14:20 Venue Room B
Speaker
  1. 1.Developing new target agents in colorectal cancer (RAS/RAF)
  2. 2.Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
    Yong Jun CHA (National Cancer Center, Korea)
  3. 3.Neoadjuvant chemotherapy in operable colon cancer
    Soohyeon LEE (Korea University Anam Hospital, Korea)

ASCO/KSMO Joint Symposium 1

Accelerating precision medicine in real-world
Date & Time Sep. 3 (Thu), 14:40-16:00 Venue Room A
Speaker
  1. 1.Latest Findings from ASCO TAPUR Study
  2. 2.Initiation of Korean TAPUR (Korean Precision Medicine Project)
    Jee Hyun KIM (Seoul National University Bundang Hospital, Korea)
  3. 3.Progress in platforms for genomic data generation and sharing

Scientific Symposium 5

The evolving landscape of systemic treatment of NSCLC
Date & Time Sep. 3 (Thu), 14:40-16:00 Venue Room B
Speaker
  1. 1.Overcoming resistance to EGFR inhibitor
    Helena YU (Memorial Sloan Kettering Cancer Center, USA)
  2. 2.Overcoming resistance to ALK inhibitor
  3. 3.Biomarkers to immunotherapy
  4. 4.Emerging strategies for immunotherapy combination
    Solange PETERS (UNIL, Switzerland)

KOSRO/KSMO Joint Symposium

Optimization of combination of local and systemic disease in stage iv and/or metastatic setting
Date & Time Sep. 3 (Thu), 14:40-16:00 Venue Room C
Speaker
  1. 1.Nasophx cancer
  2. 2.Prostate cancer
    Won PARK (Samsung Medical Center, Korea)
  3. 3.Lung cancer
    Su Ssan KIM (Asan Medical Center, Korea)

Scientific Symposium 6

GC/HBP cancers
Date & Time Sep. 3 (Thu), 14:40-16:00 Venue Room D
Speaker
  1. 1.Prospects for immunotherapy and targeted therapy in gastric cancer
    Do-Youn OH (Seoul National University Hospital, Korea)
  2. 2.Promising new treatments in biliary tract cancer
    Joon Oh PARK (Samsung Medical Center, Korea)
  3. 3.Further treatment strategies beyond PARPi therapy in pancreatic cancer
  4. 2.Challenges in systemic therapy in hepatocellular carcinoma
    Baek-Yeol RYOO (Asan Medical Center, USA)

ASCO/KSMO Joint Symposium 2

Real-world data curation and integration
Date & Time Sep. 3 (Thu), 16:20-17:40 Venue Room A
Speaker
  1. 1.CancerLINQ, ASCO's real-world data platform: challenges and perspectives
  2. 2.Research application of CancerLINQ
  3. 3.Integration of real-world data in oncology field in Korea
    Dae Young ZANG (Hallym University Sacred Heart Hospital, Korea)

Scientific Symposium 7

Functional genomics
Date & Time Sep. 3 (Thu), 16:20-17:40 Venue Room B
Speaker
  1. 1.A CRISPR-based screen for the functional assessment of BRCA1 variants
    Yongsub KIM (Asan Medical Center, Korea)
  2. 2.WRN helicase discovery as a synthetic lethal target
    Mathew Garnett (Wellcome Sanger Institute, UK)
  3. 3.WRN helicase is a synthetic lethal target in microsatellite unstable cancers
  4. 4.RNA editing enzyme ADAR1 as an immuno-oncology target
    Billy LI (Stanford University, USA)

Scientific Symposium 8

Breast cancer
Date & Time Sep. 3 (Thu), 16:20-17:40 Venue Room C
Speaker
  1. 1.Strategic approach to endocrine resistance in HR+ breast cancer
    Lajos PUSZTAI (Yale Cancer Center, USA)
  2. 2.Targeting endocrine resistance in breast cancer 
  3. 3.Implications of APOBEC mutational signature in breast cancer

Scientific Symposium 9

GU cancers
Date & Time Sep. 3 (Thu), 16:20-17:40 Venue Room D
Speaker
  1. 1.The front-line therapy in metastatic renal cell ca
    Hyo Jin LEE (Chungnam National University Hospital, Korea)
  2. 2.Novel biomarkers and targeted therapies in urothelial carcinoma
  3. 3.Clinical implementation of NGS in prostate cancer
    Jae Young JOUNG (National Cancer Center, Korea)
  4. 4.Targeted therapy in the metastatic prostate cancer

Sep. 4 (Thu)

Special Symposium 2

Opening a new chapter in clinical research of Korea BioPharm
Date & Time Sep. 4 (Fri), 09:00-10:30 Venue Room A
Speaker
  1. 1.GX-I7 (Interleukin-7-hyFc) plus immune checkpoint inhibitor in TNBC, GBM, Melanoma
    Jung Won WOO (Genexine, Inc., Korea)
  2. 2.HM95573 (RAF inhibitor) plus Cobimetinib under basket trial
    Seung Jae BAEK (Hanmi Pharm.Co.,Ltd., Korea)
  3. 3.ALT-P7 (HM2/MMAE antibody-drug conjugate) in HER2+ metastatic breast
    Sunbae LEE (Alteogen, Inc., Korea)
  4. 4.Olinvacimab (aVEGF2 mAb) plus immune checkpoint inhibitor in TNBC, GBM
    Jin-San YOO (PharmAbcine Inc., Korea)

KCSG/KSMO Joint Symposium

Date & Time Sep. 4 (Fri), 09:00-10:30 Venue Room B
Speaker
  1. 1.Collaboration with multinational study groups
  2. 2.Conducting clinical trials with multi-disciplinary collaboration
  3. 3.Early phase clinical trials: Win-win strategies for investigator and company
  4. 4.Utilizing real-world data to guide the approval and use of new drugs

JSMO/KSMO Joint Symposium

Clinical genomics : challenges and opportunities
Date & Time Sep. 4 (Fri), 09:00-10:30 Venue Room C
Speaker
  1. 1.Clinical relevance of genomics in cancer medicine in Japan
  2. 2.Implementation of genomics in medical practice in Korea
    Se-Hoon LEE (Samsung Medical Center, Korea)
  3. 3.Cancer immunogenomics
  4. 4.Application of single cell genomics in precision medicine
    Woong Yang PARK (Samsung Medical Center, Korea)

Plenary Lecture 3

Date & Time Sep. 4 (Fri), 10:50-11:30 Venue Room A
Speaker Novel target discovery based on CRISPR-Cas9 screens
Mathew Garnett (Wellcome Sanger Institute, UK)

NKK Memorial Award Lecture

Date & Time Sep. 4 (Fri), 11:30-12:10 Venue Room A
Speaker TBD

Multidisciplinary Oncology Team Education Session 1

Understanding new paradigms of oncology clinical research & practice
Date & Time Sep. 4 (Fri), 13:20-14:20 Venue Room C
Speaker
  1. 1.Toward precision targeted therapy
    Jihoon KANG (Kangbuk Samsung Hospital, Korea)
  2. 2.Boosting cancer immunotherapy
    Inho KIM (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
  3. 3.Evolving role of biomarker in clincial trial
    Yoonji CHOI (Korea University Anam Hospital, Korea)

FACO Session 1

Update of FACO Clinical Trials
Date & Time Sep. 4 (Fri), 13:20-14:20 Venue Room D
Speaker
  1. 1.Oligo-BC 1
    Shigeru IMOTO (Kyorin University, Japan)
  2. 2.PC-CURE-1

ASCO Breakthrough

KSMO-ASCO breakthrough insights: Bench to bedside research in oncology
Date & Time Sep. 4 (Fri), TBD Venue Room A
Speaker
  1. 1.Learning about Carcinogenesis and drug sensitivity from organoids
  2. 2.Clinical application of organoids for cancer diagnosis and treatment
  3. Panel Discussion
  4. 3.Microbiota, immune-tonus, and cancer: Biology
  5. 4.Microbiota, immune-tonus, and cancer: Clinical applications
  6. Panel Discussion

KSSO/KSMO Joint Symposium

Evolving role of surgery in a multidisciplinary approach
Date & Time Sep. 4 (Fri), 14:40-16:00 Venue Room B
Speaker
  1. 1.Conversion surgery in metastatic gastric cancer
    Keun-Wook Lee (Seoul National University Bundang Hospital, Korea)
  2. 2.Watch-and-wait after clinical complete response in rectal cancer
    Woo Yong LEE (Samsung Medical Center, Korea)

Multidisciplinary Oncology Team Education Session 2

Precision medicine in real-world
Date & Time Sep. 4 (Fri), 14:40-16:00 Venue Room C
Speaker
  1. 1.Precision medicine in clinical practice
    Min Hee HONG (Severance Hospital, Korea)
  2. 2.Advancing molecular tumor boards
    Yun Gyoo LEE (Kangbuk Samsung Hospital, Korea)
  3. 3.Oncology pharmacist’s role in precision medicine
    Jung Hyun KIM (Samsung Medical Center, Korea)

FACO Session 2

Advance of immuno-oncologic strategies for Asian cancer patients
Date & Time Sep. 4 (Fri), 14:40-16:00 Venue Room D
Speaker
  1. 1.Current Status of IO incorporation for NSCLC in Korea
  2. 2.Adaptation of IO agents to for GI precision medicine in China
    Xiaotian Zhang (Peking University Cancer Hospital and Institute, China)
  3. 3.Immunotherapy, CDK4/6 Inhibitors, and New Agents for Breast Cancer in Japan
    Toshimi Takano (Toranomon Hospital, Japan)

KSP/KSMO Joint Symposium

Updated cancer diagnosis platform: Present and future
Date & Time Sep. 4 (Fri), 16:20-17:40 Venue Room B
Speaker
  1. 1.Cancer diagnosis through digital platform : Present and near future
  2. 2.Telepathology consultation for frozen diagnosis
  3. 3.Development of a multiplex and multi-analyte diagnostic platform  
  4. 4.New upcoming cancer diagnosis tools

Multidisciplinary Oncology Team Education Session 3

Multidisciplinary approaches in immuno-oncology incorporated into clinical practice
Date & Time Sep. 4 (Fri), 16:20-17:40 Venue Room C
Speaker
  1. 1.Immuno-oncology in clinical practice
    Soojung LEE (Kyungpook Naitional University, Korea)
  2. 2.Biomarkers for immuno-oncology
    Chihoon MAENG (Kyung Hee University, Korea)
  3. 3.Monitoring and management of immune-related adverse events
    Shinkyo YOON (Asan Medical Center, Korea)

FACO Session 3

Current Status of Clinical Trials in Asia
Date & Time Sep. 4 (Fri), 16:20-17:40 Venue Room D
Speaker
  1. TBD